HOPE Foundation and Taiwan's Top Lung Cancer Experts Call for Seamless Integration of Early Screening, Precision Diagnostics, and Early Treatment
Taiwan's proactive approach to lung cancer prevention is recognized globally for its vision and effectiveness. In July 2022, the government launched the Lung Cancer Early Detection Program, offering biannual low-dose CT (LDCT) screenings for high-risk groups, including those with a family history of lung cancer and heavy smokers. This pioneering initiative has positioned Taiwan as an international role model in lung cancer prevention. Over the past three years, more than 210,000 screenings have led to the identification of 2,506 lung cancer cases—over 80% of which were diagnosed at an early stage, with late-stage diagnoses dropping sevenfold. Previously, late-stage diagnosis was the norm, but Taiwan's proactive policies have transformed the landscape, reversing the trend and ensuring that most initial lung cancer cases are now detected early.
During his recent visit to Taiwan, Dr. Cary Adams, CEO of the Union for International Cancer Control (UICC), commended Taiwan's National Cancer Control Program, its comprehensive cancer registry, and robust National Health Insurance (NHI) system for establishing an exemplary cancer care network. He encouraged Taiwan to further improve early lung cancer screening rates and timely access to treatment, reinforcing its status as a global public health leader. At the conference, Minister of Health and Welfare Dr. Chiu Tai-Yuan pledged ongoing cross-ministerial collaboration and policy innovation to improve early lung cancer detection and treatment. Legislator Wang Cheng-Hsu also reaffirmed his commitment to early detection and intervention, advocating for increased resources and improved legislation to ensure early-stage lung cancer patients receive comprehensive care.
ADVERTISEMENT
Leading medical experts further emphasized Taiwan's advancements. Dr. Yang, Pan-Chyr, Academician of Academia Sinica, highlighted how the LDCT screening program has driven a shift toward earlier-stage diagnosis, with research indicating it could reduce lung cancer mortality by 53%. Dr. Chen Chien-Jen, Academician of Academia Sinica emphasized that the next key challenge is ensuring early-stage patients benefit from precision diagnostics and early treatment. Dr. Yang Cheng-Ta, President of the Taiwan Lung Cancer Society, added that emerging AI technology is now capable of analyzing LDCT images to predict an individual's six-year cancer risk, which will improve identification of high-risk groups and support early intervention. Dr. Yang Chih-Hsin, President of Taiwan Association for the Study of Lung Cancer, urged early-stage patients to undergo genetic testing promptly, enabling medical teams to tailor optimal treatment plans, including surgery, targeted therapy, or immunotherapy as adjuvant treatments.
HOPE called for NHI resources to shift toward early lung cancer diagnosis and treatment, highlighting the importance of genetic testing and adjuvant therapy for high-risk early-stage patients to reduce relapse and mortality. Clinical evidence shows that adjuvant targeted therapy after surgery for stage IB–IIIA lung cancer with EGFR mutations can reduce five-year mortality by 10%, which is vital for improving outcomes and easing the burden on the healthcare system. Dr. Chen Jin-Shing, Head of Thoracic Surgery Division at National Taiwan University Hospital, advocated for priority reimbursement of adjuvant targeted therapy for patients with stage IB-IIIA lung cancer, while Dr. Chen Chih-Yi, Board Member of HOPE emphasized the importance of improving access to early genetic testing and treatment. Dr. Huang, Ming-Shyan, President of the Taiwan Clinical Oncology Society, pointed out that early-stage lung cancer treatment in Taiwan is not yet fully aligned with international guidelines, and urged that expanded screening must be matched with optimized NHI resource allocation and improved treatment access.
Other leading voices reinforced the need for comprehensive care. Dr. Wang Chin-Chou, Board Member of Taiwan Society of Pulmonary and Critical Care Medicine, stressed that while surgery is the primary treatment for early-stage lung cancer, it must be accompanied by proactive adjuvant therapy strategies and long-term follow-up. Dr. Chang Wen-Cheng, CEO of Taiwan Cancer Foundation emphasized that the integration of screening, diagnosis, and treatment is crucial to truly realize early detection and treatment, as well as maximizing the value of screening program. Dr. Chen Jen-Shi, President of Taiwan Oncology Society, recommended that in addition to current NHI and Cancer Drug Fund financing, the government should promote diverse payment mechanisms—such as co-payment models or commercial insurance to supplement the NHI system—to further improve access to early lung cancer treatment.
Uniting multiple lung cancer treatment experts from medical centers across Taiwan, a concerted effort to usher in a new era of early lung cancer screening and treatment. (Listed by institution from North to South)
· Dr. Chen Yu-Min, Director of General Chest Medicine Department, Taipei Veterans General Hospital
· Dr. Lee Kang-Yun, Attending Physician, Division of Pulmonary Medicine, Shuang Ho Hospital
· Dr. Huang Chun-Yao, Attending Physician, Division of Chest Medicine, Taipei Tzu Chi Hospital
· Dr. Tsai Chen-Liang, Director of Pulmonary and Critical Care Medicine Division, Tri-Service General Hospital
· Dr. Yeh Yu-Wen, Physician, Division of Thoracic Medicine, Shin Kong Wu Ho-Su Memorial Hospital
· Dr. Chang Sheng-Yu, Attending Physician and Leader of the Lung Cancer Team, Far Eastern Memorial Hospital
· Dr. Yang Tsung-Ying, Director of General Chest Medicine Department, Taichung Veterans General Hospital
· Dr. Hsia Te-Chun, Deputy Director, Department of Internal Medicine, China Medical University Hospital
· Dr. Lin Chien-Chung, Attending Physician, Division of Chest Medicine, National Cheng Kung University Hospital
Hashtag: #HOPEFoundation
ADVERTISEMENT
The issuer is solely responsible for the content of this announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
14 hours ago
- Zawya
HOPE Foundation and Taiwan's Top Lung Cancer Experts Call for Seamless Integration of Early Screening, Precision Diagnostics, and Early Treatment
TAIPEI, TAIWAN - Media OutReach Newswire - 16 August 2025 - Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Yet, progress is within reach. In Taiwan, thanks to the National Lung Cancer Early Detection Program, the proportion of early-stage lung cancer cases continues to rise. Against this backdrop, HOPE Foundation for Cancer Care, one of the largest cancer-focused patient advocacy groups in Taiwan, recently hosted a press conference titled "Healthy Taiwan, Leading the World – Ushering in a New Era of Early Screening and treatment of Lung Cancer". The event brought together distinguished government officials, ten leading medical authorities in lung cancer, and renowned lung cancer experts from major medical centers nationwide to chart the next phase of early lung cancer prevention and control policies. United in their commitment, participants advocated for the seamless integration of early screening, precision diagnostics, and early treatment in lung cancer care, strengthening efforts to promote early detection and intervention. Ultimately, aiming to support Taiwan in achieving its ambitious goal of reducing cancer mortality rates by one-third by 2030, setting a new international benchmark in cancer control. Taiwan's proactive approach to lung cancer prevention is recognized globally for its vision and effectiveness. In July 2022, the government launched the Lung Cancer Early Detection Program, offering biannual low-dose CT (LDCT) screenings for high-risk groups, including those with a family history of lung cancer and heavy smokers. This pioneering initiative has positioned Taiwan as an international role model in lung cancer prevention. Over the past three years, more than 210,000 screenings have led to the identification of 2,506 lung cancer cases—over 80% of which were diagnosed at an early stage, with late-stage diagnoses dropping sevenfold. Previously, late-stage diagnosis was the norm, but Taiwan's proactive policies have transformed the landscape, reversing the trend and ensuring that most initial lung cancer cases are now detected early. During his recent visit to Taiwan, Dr. Cary Adams, CEO of the Union for International Cancer Control (UICC), commended Taiwan's National Cancer Control Program, its comprehensive cancer registry, and robust National Health Insurance (NHI) system for establishing an exemplary cancer care network. He encouraged Taiwan to further improve early lung cancer screening rates and timely access to treatment, reinforcing its status as a global public health leader. At the conference, Minister of Health and Welfare Dr. Chiu Tai-Yuan pledged ongoing cross-ministerial collaboration and policy innovation to improve early lung cancer detection and treatment. Legislator Wang Cheng-Hsu also reaffirmed his commitment to early detection and intervention, advocating for increased resources and improved legislation to ensure early-stage lung cancer patients receive comprehensive care. Leading medical experts further emphasized Taiwan's advancements. Dr. Yang, Pan-Chyr, Academician of Academia Sinica, highlighted how the LDCT screening program has driven a shift toward earlier-stage diagnosis, with research indicating it could reduce lung cancer mortality by 53%. Dr. Chen Chien-Jen, Academician of Academia Sinica emphasized that the next key challenge is ensuring early-stage patients benefit from precision diagnostics and early treatment. Dr. Yang Cheng-Ta, President of the Taiwan Lung Cancer Society, added that emerging AI technology is now capable of analyzing LDCT images to predict an individual's six-year cancer risk, which will improve identification of high-risk groups and support early intervention. Dr. Yang Chih-Hsin, President of Taiwan Association for the Study of Lung Cancer, urged early-stage patients to undergo genetic testing promptly, enabling medical teams to tailor optimal treatment plans, including surgery, targeted therapy, or immunotherapy as adjuvant treatments. HOPE called for NHI resources to shift toward early lung cancer diagnosis and treatment, highlighting the importance of genetic testing and adjuvant therapy for high-risk early-stage patients to reduce relapse and mortality. Clinical evidence shows that adjuvant targeted therapy after surgery for stage IB–IIIA lung cancer with EGFR mutations can reduce five-year mortality by 10%, which is vital for improving outcomes and easing the burden on the healthcare system. Dr. Chen Jin-Shing, Head of Thoracic Surgery Division at National Taiwan University Hospital, advocated for priority reimbursement of adjuvant targeted therapy for patients with stage IB-IIIA lung cancer, while Dr. Chen Chih-Yi, Board Member of HOPEemphasized the importance of improving access to early genetic testing and treatment. Dr. Huang, Ming-Shyan, President of the Taiwan Clinical Oncology Society, pointed out that early-stage lung cancer treatment in Taiwan is not yet fully aligned with international guidelines, and urged that expanded screening must be matched with optimized NHI resource allocation and improved treatment access. Other leading voices reinforced the need for comprehensive care. Dr. Wang Chin-Chou, Board Member of Taiwan Society of Pulmonary and Critical Care Medicine, stressed that while surgery is the primary treatment for early-stage lung cancer, it must be accompanied by proactive adjuvant therapy strategies and long-term follow-up. Dr. Chang Wen-Cheng, CEO of Taiwan Cancer Foundation emphasized that the integration of screening, diagnosis, and treatment is crucial to truly realize early detection and treatment, as well as maximizing the value of screening program. Dr. Chen Jen-Shi, President of Taiwan Oncology Society, recommended that in addition to current NHI and Cancer Drug Fund financing, the government should promote diverse payment mechanisms—such as co-payment models or commercial insurance to supplement the NHI system—to further improve access to early lung cancer treatment. Uniting multiple lung cancer treatment experts from medical centers across Taiwan, a concerted effort to usher in a new era of early lung cancer screening and treatment. (Listed by institution from North to South) · Dr. Chen Yu-Min, Director of General Chest Medicine Department, Taipei Veterans General Hospital · Dr. Lee Kang-Yun, Attending Physician, Division of Pulmonary Medicine, Shuang Ho Hospital · Dr. Huang Chun-Yao, Attending Physician, Division of Chest Medicine, Taipei Tzu Chi Hospital · Dr. Tsai Chen-Liang, Director of Pulmonary and Critical Care Medicine Division, Tri-Service General Hospital · Dr. Yeh Yu-Wen, Physician, Division of Thoracic Medicine, Shin Kong Wu Ho-Su Memorial Hospital · Dr. Chang Sheng-Yu, Attending Physician and Leader of the Lung Cancer Team, Far Eastern Memorial Hospital · Dr. Yang Tsung-Ying, Director of General Chest Medicine Department, Taichung Veterans General Hospital · Dr. Hsia Te-Chun, Deputy Director, Department of Internal Medicine, China Medical University Hospital · Dr. Lin Chien-Chung, Attending Physician, Division of Chest Medicine, National Cheng Kung University Hospital Hashtag: #HOPEFoundation The issuer is solely responsible for the content of this announcement. Hope Foundation For Cancer Care
Arabian Post
16 hours ago
- Arabian Post
HOPE Foundation and Taiwan's Top Lung Cancer Experts Call for Seamless Integration of Early Screening, Precision Diagnostics, and Early Treatment
TAIPEI, TAIWAN – Media OutReach Newswire – 16 August 2025 –Lung cancer continues to be the leading cause of cancer-related deaths worldwide. Yet, progress is within reach. In Taiwan, thanks to the National Lung Cancer Early Detection Program, the proportion of early-stage lung cancer cases continues to rise. Against this backdrop,HOPE Foundation for Cancer Care, one of the largest cancer-focused patient advocacy groups in Taiwan, recently hosted a press conference titled 'Healthy Taiwan, Leading the World – Ushering in a New Era of Early Screening and treatment of Lung Cancer'. The event brought together distinguished government officials, ten leading medical authorities in lung cancer, and renowned lung cancer experts from major medical centers nationwide to chart the next phase of early lung cancer prevention and control policies. United in their commitment, participants advocated for the seamless integration of early screening, precision diagnostics, and early treatment in lung cancer care, strengthening efforts to promote early detection and intervention. Ultimately, aiming to support Taiwan in achieving its ambitious goal of reducing cancer mortality rates by one-third by 2030, setting a new international benchmark in cancer control. Taiwan's proactive approach to lung cancer prevention is recognized globally for its vision and effectiveness. In July 2022, the government launched the Lung Cancer Early Detection Program, offering biannual low-dose CT (LDCT) screenings for high-risk groups, including those with a family history of lung cancer and heavy smokers. This pioneering initiative has positioned Taiwan as an international role model in lung cancer prevention. Over the past three years, more than 210,000 screenings have led to the identification of 2,506 lung cancer cases—over 80% of which were diagnosed at an early stage, with late-stage diagnoses dropping sevenfold. Previously, late-stage diagnosis was the norm, but Taiwan's proactive policies have transformed the landscape, reversing the trend and ensuring that most initial lung cancer cases are now detected early. During his recent visit to Taiwan, Dr. Cary Adams, CEO of the Union for International Cancer Control (UICC), commended Taiwan's National Cancer Control Program, its comprehensive cancer registry, and robust National Health Insurance (NHI) system for establishing an exemplary cancer care network. He encouraged Taiwan to further improve early lung cancer screening rates and timely access to treatment, reinforcing its status as a global public health leader. At the conference, Minister of Health and Welfare Dr. Chiu Tai-Yuan pledged ongoing cross-ministerial collaboration and policy innovation to improve early lung cancer detection and treatment. Legislator Wang Cheng-Hsu also reaffirmed his commitment to early detection and intervention, advocating for increased resources and improved legislation to ensure early-stage lung cancer patients receive comprehensive care. ADVERTISEMENT Leading medical experts further emphasized Taiwan's advancements. Dr. Yang, Pan-Chyr, Academician of Academia Sinica, highlighted how the LDCT screening program has driven a shift toward earlier-stage diagnosis, with research indicating it could reduce lung cancer mortality by 53%. Dr. Chen Chien-Jen, Academician of Academia Sinica emphasized that the next key challenge is ensuring early-stage patients benefit from precision diagnostics and early treatment. Dr. Yang Cheng-Ta, President of the Taiwan Lung Cancer Society, added that emerging AI technology is now capable of analyzing LDCT images to predict an individual's six-year cancer risk, which will improve identification of high-risk groups and support early intervention. Dr. Yang Chih-Hsin, President of Taiwan Association for the Study of Lung Cancer, urged early-stage patients to undergo genetic testing promptly, enabling medical teams to tailor optimal treatment plans, including surgery, targeted therapy, or immunotherapy as adjuvant treatments. HOPE called for NHI resources to shift toward early lung cancer diagnosis and treatment, highlighting the importance of genetic testing and adjuvant therapy for high-risk early-stage patients to reduce relapse and mortality. Clinical evidence shows that adjuvant targeted therapy after surgery for stage IB–IIIA lung cancer with EGFR mutations can reduce five-year mortality by 10%, which is vital for improving outcomes and easing the burden on the healthcare system. Dr. Chen Jin-Shing, Head of Thoracic Surgery Division at National Taiwan University Hospital, advocated for priority reimbursement of adjuvant targeted therapy for patients with stage IB-IIIA lung cancer, while Dr. Chen Chih-Yi, Board Member of HOPE emphasized the importance of improving access to early genetic testing and treatment. Dr. Huang, Ming-Shyan, President of the Taiwan Clinical Oncology Society, pointed out that early-stage lung cancer treatment in Taiwan is not yet fully aligned with international guidelines, and urged that expanded screening must be matched with optimized NHI resource allocation and improved treatment access. Other leading voices reinforced the need for comprehensive care. Dr. Wang Chin-Chou, Board Member of Taiwan Society of Pulmonary and Critical Care Medicine, stressed that while surgery is the primary treatment for early-stage lung cancer, it must be accompanied by proactive adjuvant therapy strategies and long-term follow-up. Dr. Chang Wen-Cheng, CEO of Taiwan Cancer Foundation emphasized that the integration of screening, diagnosis, and treatment is crucial to truly realize early detection and treatment, as well as maximizing the value of screening program. Dr. Chen Jen-Shi, President of Taiwan Oncology Society, recommended that in addition to current NHI and Cancer Drug Fund financing, the government should promote diverse payment mechanisms—such as co-payment models or commercial insurance to supplement the NHI system—to further improve access to early lung cancer treatment. Uniting multiple lung cancer treatment experts from medical centers across Taiwan, a concerted effort to usher in a new era of early lung cancer screening and treatment. (Listed by institution from North to South) · Dr. Chen Yu-Min, Director of General Chest Medicine Department, Taipei Veterans General Hospital · Dr. Lee Kang-Yun, Attending Physician, Division of Pulmonary Medicine, Shuang Ho Hospital · Dr. Huang Chun-Yao, Attending Physician, Division of Chest Medicine, Taipei Tzu Chi Hospital · Dr. Tsai Chen-Liang, Director of Pulmonary and Critical Care Medicine Division, Tri-Service General Hospital · Dr. Yeh Yu-Wen, Physician, Division of Thoracic Medicine, Shin Kong Wu Ho-Su Memorial Hospital · Dr. Chang Sheng-Yu, Attending Physician and Leader of the Lung Cancer Team, Far Eastern Memorial Hospital · Dr. Yang Tsung-Ying, Director of General Chest Medicine Department, Taichung Veterans General Hospital · Dr. Hsia Te-Chun, Deputy Director, Department of Internal Medicine, China Medical University Hospital · Dr. Lin Chien-Chung, Attending Physician, Division of Chest Medicine, National Cheng Kung University Hospital Hashtag: #HOPEFoundation ADVERTISEMENT The issuer is solely responsible for the content of this announcement.
Arabian Post
5 days ago
- Arabian Post
Top 1 Wearable Pump Brand in 2024, Momcozy Launches ‘More Than Pumping' for Breastfeeding Month
'More Than Pumping' will amplify trusted voices, offer emotional support, and provide expert guidance to create a breastfeeding-friendly environment where mothers feel understood and supported SINGAPORE – Media OutReach Newswire – 12 August 2025 – As Breastfeeding Awarenesss Month begins, Momcozy, the global No.1 wearable breast pump brand, proudly launches its newest initiative 'More Than Pumping, Real Support with Trusted Voices'. The initiative highlights the company's mission to not only meet the functional needs of breastfeeding moms, but also deliver culturally conscious emotional and educational support. Top 1 Wearable Pump Brand in 2024, Momcozy Launches 'More Than Pumping' for Breastfeeding Month Following its success in over 60 countries and regions, Momcozy is now bringing its award-winning products and trusted community support to mothers across Singapore, Malaysia, Indonesia, Vietnam, Thailand, Philippines, India, Japan and Australia and more — strengthening its footprint in one of the world's fastest-growing maternal care markets-Asia Pacific Region. ADVERTISEMENT 'At Momcozy, we believe a breast pump is more than just a tool—it belongs to a whole system of care,' said Ellen Zhou, APAC Marketing Director, at Momcozy. 'Designing for moms means understanding their realities—the long nights, the pumping breaks between meetings, the quiet moments of doubt, and the powerful ones of pride. The 'More Than Pumping' campaign draws on expert advice, lived experiences, and stories from over four million moms worldwide, so every mother feels recognised, supported, and empowered—no matter how she chooses to feed. This blend of innovation and genuine care has earned Momcozy its position as the global No.1 wearable breast pump brand by market share. With #MomcozyRealSupport, the company hopes to bring mothers more comfort, confidence, and calm each day.' Star Product Lineup: Innovation Moms Trust From breast pumps to maternity pillows, nursing bras, massagers, feeding gear like bottle washer and sterilizer, Milk cooler and warmers, and more, Momcozy supports mothers through every stage of pregnancy, nursing, and parenting—encouraging them to stay true to themselves while caring for their little ones. Beloved by millions worldwide and rapidly growing in the region. Global Voices, Local Relevance: Becca Kufrin Leads the Way Momcozy's U.S. Brand Ambassador Becca Kufrin shares her breastfeeding journey with 'My Breastfeeding Moments' story. Her vulnerable reflections underscore the challenges and triumphs of new motherhood and reinforce the brand's core message: breastfeeding is more than pumping — it's reclaiming a sense of self. For 'More Than Pumping', Becca is opening up about her raw experiences in finding flexibility in chaos, strength in uncertainty, and pride in every moment. She shares her story to remind moms everywhere that breastfeeding is more than pumping – it's about reclaiming a sense of self, finding flexibility, and honoring every ounce. She invites moms to join the conversation and feel proud of every effort. ADVERTISEMENT In Asia-Pacific, Momcozy will feature local experts and real mothers in different ways, addressing culturally specific breastfeeding challenges . Clinical Credibility and Expert-Led Education Motherhood comes with endless questions, and having reliable, professional guidance is essential. To meet this need, Momcozy established the Medical Advisory Board (MAB) — led by Dr. Fran Haydanek, Playforth, and Latham Thomas — bringing together expertise in pediatrics, lactation, maternal health, and holistic wellness. The board guides product design, co-creates educational content, and ensures all support is science-backed, empathetic, and relevant to mothers worldwide Inclusive, Empowering Conversations: Collaborations with NAPS and Mama Glow In partnership with trusted maternal care voices NAPS and Mama Glow, Momcozy is delivering programs that resonate with mothers worldwide, including an enthusiastic following in Asia Pacific Region. Kicking off in August, Momcozy and NAPS will launch a four-part webinar series airing every Friday at 1 PM EST. Covering essential topics like pumping strategies and nighttime routines, the series offers practical, clinically grounded guidance for new parents. On August 5, Momcozy and Mama Glow will debut their first-ever joint program — the downloadable digital resource 'Build Your Feeding Village', providing culturally mindful breastfeeding support for families. Later in the month, on August 27, Momcozy will join the 'Feeding Our Futures' livestream panel, exploring the cultural importance and systemic challenges of breastfeeding. Designed by Care, Backed by Innovation Recognized as the Global No.1 Wearable Breast Pump Brand with a 2024 global market share of 19.32% (Based on global market share of wearable breast pumps, Grand View Research 2024), Momcozy has become the trusted choice of over 4 million mothers across more than 60 countries and regions. With 49 industry awards — including the Red Dot Design Award, Best of the Bump Awards, Made for Mums Awards, and Mother & Baby Awards — Momcozy's designs are recognized worldwide for innovation, quality, and comfort. For example, Winner of the Kind + Jugend ASEAN 2025 Innovation Award, the M9 wearable pump exemplifies Momcozy's dedication to supporting mothers through thoughtful, expert-informed design. Engineered for comfort and convenience, the M9 is the ideal solution for moms on the go. In Asia pacific region, products are available via the Momcozy official website, Amazon, Shopee, TikTok Shop, and through local mother-and-baby retail chains, making premium maternal care both accessible and convenient. Hashtag: #Momcozy The issuer is solely responsible for the content of this announcement. About Momcozy Since its founding in 2018, Momcozy has rapidly emerged as a leader in the FemTech space, offering a range of products designed to support mothers and babies from pregnancy through postpartum and beyond. With its wearable breast pumps, nursing bras, and other essential products that seamlessly integrate into the lives of modern mothers, the brand has redefined maternal care. In 2024, its wearable breast pump claimed the highest global sales revenue in its category*. Over the years, Momcozy has amassed a huge community of over four million** mothers across 60 countries and around two million followers across its social media platforms. It holds more than 520 authorized patents and over 330 registered trademarks, with products available both on the brand's website and through major retailers including Babylist, Walmart, Target, and Amazon. Momcozy stays deeply committed to innovation and comfort. Its mission is to offer comprehensive solutions that empower mothers with the support they need at every stage of their journey. *Based on global market share of wearable breast pumps, Grand View Research 2024 **Data as of July 2025 from Amazon's official platform.
